---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-23-000076"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:31:51.689104+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q2 2023: ZORYVE revenue $4.8M (+72% QoQ); net loss $71M

## Summary
- Total revenues $5.2M; ZORYVE net product revenue $4.8M, up 72% sequentially.
- Net loss $71.0M ($1.16 per share) vs $67.4M ($1.31) in Q2 2022.
- Cash and marketable securities $269.6M as of June 30 vs $410.8M at Dec 31, 2022.
- Commercial coverage expanded to >130M lives (all 3 largest PBMs) for ZORYVE.
- FDA action date Dec 16, 2023 for roflumilast foam in seborrheic dermatitis; sNDA for atopic dermatitis expected late Q3/early Q4 2023.

## SEC filing metadata
- accession: 0001787306-23-000076
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000076/0001787306-23-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000076/arqt-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-23-000076
- JSON: https://secwatch.observer/filing/0001787306-23-000076.json
- Plain text: https://secwatch.observer/filing/0001787306-23-000076.txt

## Key facts
- Earnings Releases
  Arcutis Biotherapeutics, Inc. reported quarter ended June 30, 2023 results: revenue $4.8 million.
  - Period: quarter ended June 30, 2023
  - Revenue: $4.8 million
  - Result: reported results
  source text: Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update • Achieved total revenues of $5.2 million in the second quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000076/0001787306-23-000076-index.htm
- Earnings Releases
  Arcutis Biotherapeutics, Inc. reported quarter ended June 30, 2023 results: revenue $4.8 million.
  - Period: quarter ended June 30, 2023
  - Revenue: $4.8 million
  - Result: reported results
  source text: Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of 2023, driven by nearly 40% demand growth as well as gross-to-net improvement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000076/0001787306-23-000076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.